You are here:
Myelodysplastic syndromes (MDS) low risk patients; transfusion-dependent and relapsed after or refractory to prior therapy (refractory to ESA).
No judgement
Clinical trials
Imetelstat
Oncology and Hematology
New medicine (specialité)
AML / MDS
Geron
Enzyme inhibitor
Intravenous
Intravenous drip
Intermural (MSZ)
Fabrikant: Geron Corp. A first-in-class telomerase inhibitor.
Centralised (EMA)
2019
2020
No
Weesgeneesmiddel in de US niet in EU.
RBC transfusies
1 times every 4 weeks
7,5 mg/kg
NCT02598661
< 737
Market share is generally not included unless otherwise stated.
NKR
Aantal diagnoses myelodysplastisch syndroom in 2016: 737.
There is currently nothing known about the expected cost.
There is currently nothing known about the possible total cost.
There is currently nothing known about off label use.
Yes
Primary or secondary myelofibrosis.
SPS; ASH2018, paper no: 685
There is currently no futher information available.
Understanding of expected market entry of innovative medicines